Tag Archives: ONXX

Healthcare Sector Roundup: Wright Medical (NASDAQ:WMGI), Cyberonics (NASDAQ:CYBX) – WMGI, CYBX, STJ, ONXX, DXCM, MMSI

Posted on February 23, 2013 by Thomas Vedder

Healthcare sector finished higher on Friday trading session and sector moved up +0.88%. If we look at the best movers of the sector so Onyx Pharmaceuticals, Inc (NASDAQ:ONXX) and DexCom, Inc (NASDAQ:DXCM) were major percentage gainers while major percentage losers …

Posted in Healthcare, Latest Headlines | Tagged Cyberonics, CYBX, DexCom, DXCM, Merit Medical Systems, MMSI, NASDAQ:CYBX, NASDAQ:DXCM, NASDAQ:MMSI, NASDAQ:ONXX, NASDAQ:WMGI, NYSE:STJ, ONXX, Onyx Pharmaceuticals, St. Jude Medical, STJ, WMGI, Wright Medical Group | Comments Off

Celsion (NASDAQ:CLSN) Reports Narrower Loss in the Third Quarter – CLSN, ONXX, IMUC, GERN

Posted on November 13, 2012 by Geoff Noir

Celsion Corporation (NASDAQ:CLSN) announced a loss of $6.0 million or $0.18 a share in the third quarter on Monday, evaluated against $6.4 million or $0.25 a share in the similar three months period previous year.

Thomson Reuters 3 analysts surveyed …

Posted in Healthcare, Latest Headlines | Tagged Celsion, CLSN, GERN, Geron, ImmunoCellular Therapeutics, IMUC, NASDAQ:CLSN, NASDAQ:GERN, NASDAQ:ONXX, NYSE:IMUC, ONXX, Onyx Pharmaceuticals | Comments Off

Healthcare Stocks Get Investors Affection; Onyx Pharmaceuticals (ONXX) and Bayer’s Get FDA approval for Colorectal Cancer Drug While AspenBio (APPY)’s Four Board Members Quit – ONXX, APPY, PFE, APPY, ERB, CYTX

Posted on September 28, 2012 by Geoff Noir

Last trading session’s data showed that Healthcare sector reacted positively with +0.70% change. AspenBio Pharma, Inc. (NASDAQ:APPY) and ERBA Diagnostics Inc. (NYSEAMEX:ERB) were major gainers in this sector while major decliner was Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX).

The South San …

Posted in Healthcare, Latest Headlines | Tagged APPY, AspenBio, Cytori Therapeutics, CYTX, ERB, ERBA Diagnostics, NASDAQ:APPY, NASDAQ:CYTX, NASDAQ:ONXX, NYSE:PFE, NYSEAMEX:ERB, ONXX, Onyx, PFE, Pfizer | Comments Off

Onyx Pharmaceuticals (NASDAQ:ONXX) Blood Cancer Drug Kyprolis Wins FDA Approval – ONXX, AVEO, CELG, AMGN

Posted on July 23, 2012 by Thomas Vedder

The South San Francisco, California-based Onyx Pharmaceuticals, Inc’s (NASDAQ:ONXX) treatment for a deadly blood cancer got United States support, offering the corporations its primary wholly owned medicine to sell.

The Food and Drug Administration reported in a statement on Friday …

Posted in Healthcare, Latest Headlines | Tagged Amgen, AMGN, AVEO, CELG, Celgene, NASDAQ:AMGN, NASDAQ:AVEO, NASDAQ:CELG, NASDAQ:ONXX, ONXX, Onyx | Comments Off

What the fuss RIMM, Potash, Merge Healthcare and Onyx Pharmaceuticals?

Posted on November 28, 2011 by Martin Timble

In this report: Merge Healthcare (NASDAQ:MRGE), Onyx Pharmaceuticals (NASDAQ:ONXX), Research in Motion (NASDAQ:RIMM) and Potash (NYSE:POT).

Merge Healthcare (NASDAQ:MRGE) is trading over 14 percent higher today after the company announced that it will launch its new cloud based platform during …

Posted in Latest Headlines, Reports | Tagged analyst, Blackberry, bloomberg, business, Buy, cancer therapy, downgraded, firm, Merge Healthcare, Merge Honeycomb, MRGE, NASDAQ, NASDAQ:MRGE, NASDAQ:ONXX, NASDAQ:RIMM, NYSE, NYSE:POT, ONXX, Onyx Pharmaceuticals, platform, POT, Potash, quarter, rating, report, Research in Motion, RIMM, sale, scotia, Stern Agee, stock, strategic options, trading, upgrade | Comments Off

What the Fuss Onyx Pharmaceuticals, Phillips-Van Heusen and Priceline.com?

Posted on October 12, 2011 by Cameron White

In this report: ONYX Pharmaceuticals Inc. (NASDAQ:ONXX), Phillips-Van Heusen (NYSE:PVH) and Priceline.com (NASDAQ:PCLN).

ONYX Pharmaceuticals Inc. (NASDAQ:ONXX) is trading more than 6.5 percent higher after the company settled its lawsuit against Bayer AG over its collaboration on the cancer drug …

Posted in Latest Headlines, Reports | Tagged agreed, analyst, Bayer AG, Buy, cancer drug, drugmaker, earnings, expect, firm, forecast, forecasted, initiation, Jefferies, lawsuit, NASDAQ, NASDAQ:ONXX, NASDAQ:PCLN, Nexavar, NYSE, NYSE:PVH, online travel agent, ONXX, ONYX Pharmaceuticals Inc., PCLN, Phillips-Van Heusen, price objective, Priceline.com, PVH, quarter, range, rates, rating, Regorafenib, trade, trading | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.